Geode Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-669,035
| Closed | -$25.2M | – | 4776 |
|
|
2021
Q1 | $25.2M | Buy |
669,035
+39,343
| +6% | +$981K | ﹤0.01% | 1727 |
|
|
2020
Q4 | $10.7M | Buy |
629,692
+90,236
| +17% | +$1.13M | ﹤0.01% | 2127 |
|
|
2020
Q3 | $2.54M | Buy |
539,456
+43,196
| +9% | +$219K | ﹤0.01% | 2753 |
|
|
2020
Q2 | $3.03M | Sell |
496,260
-42,529
| -8% | -$175K | ﹤0.01% | 2605 |
|
|
2020
Q1 | $1.22M | Buy |
538,789
+22,965
| +4% | +$97.5K | ﹤0.01% | 2927 |
|
|
2019
Q4 | $2.37M | Buy |
515,824
+50,227
| +11% | +$199K | ﹤0.01% | 2913 |
|
|
2019
Q3 | $1.8M | Buy |
465,597
+15,183
| +3% | +$83.3K | ﹤0.01% | 2998 |
|
|
2019
Q2 | $2.71M | Buy |
450,414
+22,025
| +5% | +$211K | ﹤0.01% | 2752 |
|
|
2019
Q1 | $5.74M | Buy |
428,389
+18,688
| +5% | +$213K | ﹤0.01% | 2251 |
|
|
2018
Q4 | $3.81M | Buy |
409,701
+38,601
| +10% | +$459K | ﹤0.01% | 2387 |
|
|
2018
Q3 | $5.17M | Buy |
371,100
+6,444
| +2% | +$95.8K | ﹤0.01% | 2337 |
|
|
2018
Q2 | $5.76M | Buy |
364,656
+35,309
| +11% | +$616K | ﹤0.01% | 2247 |
|
|
2018
Q1 | $5.66M | Buy |
329,347
+67,820
| +26% | +$1.32M | ﹤0.01% | 2164 |
|
|
2017
Q4 | $5.73M | Buy |
261,527
+1,792
| +0.7% | +$57.6K | ﹤0.01% | 2133 |
|
|
2017
Q3 | $10.6M | Buy |
259,735
+17,547
| +7% | +$551K | ﹤0.01% | 1680 |
|
|
2017
Q2 | $7.29M | Buy |
242,188
+2,553
| +1% | +$79.7K | ﹤0.01% | 1875 |
|
|
2017
Q1 | $8.66M | Sell |
239,635
-10,792
| -4% | -$476K | ﹤0.01% | 1715 |
|
|
2016
Q4 | $12.5M | Buy |
250,427
+7,161
| +3% | +$376K | 0.01% | 1437 |
|
|
2016
Q3 | $12.8M | Buy |
243,266
+21,297
| +10% | +$1.02M | 0.01% | 1327 |
|
|
2016
Q2 | $9.18M | Buy |
221,969
+33,751
| +18% | +$1.47M | 0.01% | 1498 |
|
|
2016
Q1 | $7.65K | Buy |
188,218
+4,679
| +3% | +$161K | ﹤0.01% | 1575 |
|
|
2015
Q4 | $7.62M | Buy |
183,539
+46,213
| +34% | +$1.55M | ﹤0.01% | 1571 |
|
|
2015
Q3 | $2.11M | Buy |
137,326
+7,839
| +6% | +$168K | ﹤0.01% | 2404 |
|
|
2015
Q2 | $3.22M | Sell |
129,487
-11,754
| -8% | -$262K | ﹤0.01% | 2202 |
|
|
2015
Q1 | $3.23M | Buy |
141,241
+69,864
| +98% | +$1.76M | ﹤0.01% | 2126 |
|
|
2014
Q4 | $1.93M | Buy |
71,377
+18,114
| +34% | +$312K | ﹤0.01% | 2460 |
|
|
2014
Q3 | $624K | Sell |
53,263
-7
| -0% | -$88 | ﹤0.01% | 3057 |
|
|
2014
Q2 | $828K | Buy |
53,270
+7,799
| +17% | +$112K | ﹤0.01% | 2903 |
|
|
2014
Q1 | $893K | Buy |
45,471
+15,899
| +54% | +$270K | ﹤0.01% | 2856 |
|
|
2013
Q4 | $496K | Buy |
+29,572
| New | +$367K | ﹤0.01% | 3094 |
|
Geode Capital Management's FPRX Position: Q2 2021 in Review
Geode Capital Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 669,035 shares — an estimated $25.2M sold.
Geode Capital Management first reported a position in FPRX in Q4 2013 and held it in 30 quarters. The position peaked at $25.2M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Geode Capital Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Geode Capital Management sold 669,035 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $25.2M.
- Geode Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q4 2013 and held it in 30 quarters.
- Geode Capital Management's Five Prime Therapeutics, Inc. position peaked at $25.2M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Geode Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.